Avacta Therapeutics Presents FAP-Dox Data at International Congress
Avacta Therapeutics, a pioneering life sciences company, is set to present an exciting update regarding their innovative drug FAP-Dox (AVA6000) at an esteemed international oncology congress. This event will spotlight groundbreaking research and clinical advancements in targeted cancer treatments that can revolutionize patient care.
Significance of FAP-Dox
FAP-Dox is notable for its unique formulation as a peptide drug conjugate combining doxorubicin—an established chemotherapy agent—with a specific peptide designed to be cleaved in the tumor microenvironment. This cutting-edge approach could significantly enhance the efficacy of treatment while minimizing damage to surrounding healthy tissues.
Phase 1a Trial Insights
The presentation will focus on a recent analytical exploration of the Phase 1a clinical trial, which involves patients diagnosed with FAP-positive solid tumors. The recruitment for Phase 1a has been completed, and the company is actively enrolling participants for multiple dose-expansion cohorts in the subsequent Phase 1b trial.
Details of the Presentation
Presentation Title
“A Phase I trial of FAP-Dox (AVA6000), a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate.”
Session Information
The presentation is scheduled for October 17, specifically during the Developmental Therapeutics session. Attendees can expect detailed insights at 19:40 - 20:00 in the Berlin Auditorium, Hub 27. The presentation will carry the abstract number 964P, and it will be delivered by the esteemed speaker William D. Tap.
Anticipated Investor Event
Following this insightful presentation, Avacta aims to host an investor event where they will share further insights regarding the results and future directions of FAP-Dox. This will provide an opportunity for the investing community to engage directly and discuss the implications of these findings.
Avacta’s Commitment to Innovation
The pre|CISION® platform employed by Avacta Therapeutics serves as a revolutionary delivery system focused on enhancing the potency of cancer therapies. By leveraging a tumor-specific protease, this platform is designed to direct high-impact treatments precisely where they are needed, improving outcomes for patients while reducing systemic side effects.
Understanding the pre|CISION® Platform
This unique platform utilizes an anticancer payload linked to a proprietary peptide that targets fibroblast activation protein (FAP), primarily found in solid tumors. The system smartly cleaves and releases the therapeutic agent within the tumor itself, thus ensuring higher concentrations of medication at the action site while sparing healthy tissues.
Engaging with Avacta
For further inquiries or detailed information about FAP-Dox or ongoing clinical trials, interested parties are encouraged to reach out directly to the Avacta Communications team.
Frequently Asked Questions
What is FAP-Dox (AVA6000)?
FAP-Dox is a peptide drug conjugate designed to deliver chemotherapy directly to FAP-positive solid tumors, enhancing efficacy and reducing toxicity.
When will Avacta present its data?
Avacta will present its findings on October 17 during the ESMO Congress.
How does the pre|CISION® platform work?
The pre|CISION® platform utilizes tumor-specific proteases to cleave drug conjugates in the tumor microenvironment, ensuring higher potency where needed.
Who is leading the presentation?
William D. Tap will be the speaker for the presentation at the ESMO Congress.
How can investors get more information?
Investors can attend Avacta's upcoming event after the ESMO presentation or contact the company directly for further insights.
